Key result
Growth hormone therapy in peripubertal boys with idiopathic short stature significantly increased height velocity during the first year of treatment compared to no treatment (9.3 vs 5.3 cm/year, p < 0.001).
Why the study?
Does recombinant growth hormone improve final height in peripubertal boys with idiopathic short stature and subnormal integrated GH concentration?
Cohort (n=28)
Does recombinant growth hormone improve final height in peripubertal boys with idiopathic short stature and subnormal integrated GH concentration?
Absolute Event Rate: 9.3% vs 5.3%
p-value: p=< 0.001
Growth hormone therapy enables peripubertal boys with idiopathic short stature and subnormal integrated GH concentration to reach their target and predicted final heights.
No takes yet. Share an insight, caveat, or question.
GH therapy was associated with greater first-year height velocity in peripubertal boys with ISS; leaves open effects on final height.
Zadik et al. (2008) conducted a cohort in idiopathic short stature with subnormal integrated concentration of growth hormone (n=28). recombinant growth hormone (GH) vs. untreated children was evaluated on height velocity during the 1st year of treatment (p=< 0.001). Growth hormone therapy in peripubertal boys with idiopathic short stature significantly increased height velocity during the first year of treatment compared to no treatment (9.3 vs 5.3 cm/year, p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: